Newborn screening for beta-ketothiolase deficiency: evidence from a systematic review
Abstract
Background: Newborn screening aims to reduce morbidity and mortality through early detection of treatable conditions. Beta-ketothiolase deficiency (βKT) is a rare metabolic disorder associated with severe ketoacidotic crises, but its inclusion in screening programmes remains uncertain due to limited evidence on effectiveness.
Methods: A systematic review was conducted to assess the clinical effectiveness of newborn screening for βKT using tandem mass spectrometry (MS/MS) compared with no screening. Searches included systematic reviews, health technology assessments, and primary studies (2019–2026). Study selection followed PRISMA guidelines. Evidence was synthesised using an Evidence-to-Decision framework. A national survey of screening programmes was also performed.
Results: Seventeen studies were included, mainly observational and retrospective, with no comparative studies identified. Screening programmes covered over 26 million newborns internationally, with high participation rates (>90%). MS/MS is widely implemented, but evidence on diagnostic accuracy is limited, with uncertain sensitivity and low predictive value due to low disease prevalence. Clinical effectiveness remains unclear, as no studies directly compare screened and unscreened populations. Observational data suggest earlier diagnosis may reduce severity, but findings are inconsistent and non-causal.
Conclusions: Evidence supporting newborn screening for βKT is limited and of low quality, preventing robust conclusions on its impact on health outcomes. While screening is technically feasible and widely implemented, key uncertainties remain regarding effectiveness and test performance. Further research is needed to support evidence-based decision-making.
Key messages: • Evidence on newborn screening for beta-ketothiolase deficiency is limited and insufficient to demonstrate clinical effectiveness
• Despite high feasibility, key uncertainties in test performance and outcomes hinder evidence-based screening decisions.
Related
- A Systematic Review of Metachromatic Leukodystrophy Newborn Screening: Transitioning from Pilot Studies to the Real World.
- Evidence gaps hindering implementation of newborn screening for galactosemia
- Newborn Screening for X-Linked Adrenoleukodystrophy: A Systematic Literature Review.
- Cost-effectiveness of newborn screening for phenylketonuria and congenital hypothyroidism in Hubei, China.
- Incidental maternal glutaric aciduria type I detection through newborn screening: A case report
BibTeX
@article{pazvalinas2026newborn,
title = {{Newborn screening for beta-ketothiolase deficiency: evidence from a systematic review}},
author = {L Paz-Valinas and MC Maceira-Rozas and B Casal-Acción and MJ Faraldo-Vallés},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.1487},
url = {https://doi.org/10.1093/eurpub/ckag169.1487},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Newborn screening for beta-ketothiolase deficiency: evidence from a systematic review
AU - L Paz-Valinas
AU - MC Maceira-Rozas
AU - B Casal-Acción
AU - MJ Faraldo-Vallés
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.1487
UR - https://doi.org/10.1093/eurpub/ckag169.1487
AB - Background: Newborn screening aims to reduce morbidity and mortality through early detection of treatable conditions. Beta-ketothiolase deficiency (βKT) is a rare metabolic disorder associated with severe ketoacidotic crises, but its inclusion in screening programmes remains uncertain due to limited evidence on effectiveness. Methods: A systematic review was conducted to assess the clinical effectiveness of newborn screening for βKT using tandem mass spectrometry (MS/MS) compared with no screening. Searches included systematic reviews, health technology assessments, and primary studies (2019–2026). Study selection followed PRISMA guidelines. Evidence was synthesised using an Evidence-to-Decision framework. A national survey of screening programmes was also performed. Results: Seventeen studies were included, mainly observational and retrospective, with no comparative studies identified. Screening programmes covered over 26 million newborns internationally, with high participation rates (>90%). MS/MS is widely implemented, but evidence on diagnostic accuracy is limited, with uncertain sensitivity and low predictive value due to low disease prevalence. Clinical effectiveness remains unclear, as no studies directly compare screened and unscreened populations. Observational data suggest earlier diagnosis may reduce severity, but findings are inconsistent and non-causal. Conclusions: Evidence supporting newborn screening for βKT is limited and of low quality, preventing robust conclusions on its impact on health outcomes. While screening is technically feasible and widely implemented, key uncertainties remain regarding effectiveness and test performance. Further research is needed to support evidence-based decision-making. Key messages: • Evidence on newborn screening for beta-ketothiolase deficiency is limited and insufficient to demonstrate clinical effectiveness • Despite high feasibility, key uncertainties in test performance and outcomes hinder evidence-based screening decisions.
SN - 1101-1262
SN - 1464-360X
ER -